Tumor Treating Fields

DEVICE5 trials

Sponsors

Adilia Hormigo, Providence Health & Services, Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, NovoCure Ltd.

Conditions

Biliary Tract Cancers (BTC)Brain TumorCancer of BrainGlioblastomaGlioblastoma MultiformeMetastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Active, not recruitingNCT03223103

Adilia HormigoGlioblastoma

Start: 2018-03-01End: 2029-05-12Updated: 2025-09-10

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

TerminatedNCT03705351

Providence Health & ServicesBrain Tumor, Cancer of Brain, Glioblastoma +1

Start: 2019-12-02End: 2022-02-24Updated: 2024-03-04

Phase 2

TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

RecruitingNCT06353360

Jiangsu Healthy Life Innovation Medical Technology Co., LtdGlioblastoma Multiforme

Start: 2024-04-30End: 2026-03-09Target: 30Updated: 2024-08-09

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

CompletedNCT06390059

NovoCure Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2023-08-21End: 2025-11-18Updated: 2026-09-04

Unknown Phase

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

RecruitingNCT06611345

Jiangsu Healthy Life Innovation Medical Technology Co., LtdBiliary Tract Cancers (BTC)

Start: 2024-10-21End: 2027-03-30Target: 60Updated: 2024-10-26

Related Papers

Tumor treating fields suppress tumor cell growth and induce immunogenic cell death biomarkers in biliary tract cancer cell lines.

2025-08-20

CTIM-10. PHASE 1 TRIAL OF PERSONALIZED NEOANTIGEN VACCINES IN COMBINATION WITH STANDARD CARE TO TREAT GLIOBLASTOMA

Neuro-Oncology2024-11-011 citations

Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting

Cancer Research2023-04-144 citations

334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients

Regular and Young Investigator Award Abstracts2021-11-013 citations

CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2020-11-015 citations

EPCO-22. IDENTIFYING NEOANTIGENS FOR A PERSONALIZED MUTATION-DERIVED GENOMIC VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2020-11-01

OpenVax: An Open-Source Computational Pipeline for Cancer Neoantigen Prediction.

2020-01-0127 citations